Rein Therapeutics, Inc. (RNTX) stock
RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.36−0.04 (-10.90%)
Close on Nov 17, 2026Market cap $30.75MP/E –Yield 0.00%
Earnings
Rein Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q1 FY2025
–
EPS, Q1 FY2025
-$0.25
-$0.86 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Rein Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q1 FY2025ended Mar 31, 2025 | May 15, 2025during market hours | – | – | -$0.25 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 14, 2024during market hours | – | – | -$0.27 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 14, 2024during market hours | – | – | -$0.45 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 15, 2024during market hours | – | – | -$0.86 | Release |
| Q4 FY2023ended Dec 31, 2023 | Apr 15, 2024during market hours | – | – | -$1.54 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Rein Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Rein Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Rein Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- News
- News
- News
- News
- Results
- Results
- Results
- Results
- News
- Results
- Update
- Update
- Update
See a number that looks wrong?